Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KIF5B | P33176 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564423 | 0.79 | HTT (0.56) | RETEGFRKIF5BKDM4EALDH1A1 | |
| SCHEMBL5569127 | 0.79 | MEN1 (0.48) | TP53KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL5569470 | 0.75 | EGFR (0.58) | RETEGFRKDM4EALDH1A1HPGD | |
| SCHEMBL5564595 | 0.75 | ABCG2 (0.67) | RETEGFRKIF5BKDM4EALDH1A1 | |
| SCHEMBL5569119 | 0.74 | TP53 (0.50) | RETEGFRTP53KIF5BMAPT | |
| SCHEMBL5564904 | 0.72 | KDR (0.42) | RETEGFRTP53KIF5BMAPT | |
| SCHEMBL5568069 | 0.71 | JAK2 (0.56) | EGFRTP53KDM4EALDH1A1MAPT | |
| SCHEMBL5569346 | 0.71 | CCNT1 (0.50) | EGFRKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL5569113 | 0.71 | EGFR (0.53) | EGFRKDM4EALDH1A1HPGDKDR | |
| SCHEMBL5570053 | 0.71 | HPGD (0.52) | EGFRKDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | RET 2776/4885EGFR 1445/4885TP53 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.